IL-17A binding agent and uses thereof
US9862765B2 · kind B2 · utility
2Cited by
3References
25Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 27, 2014 |
| Grant date | Jan 9, 2018 |
| Priority date | — |
| Expiry date | Oct 27, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.